Zoetis Inc
NYSE:ZTS
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
145.54
200.09
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Zoetis Inc
Zoetis Inc
Revenue
Zoetis Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zoetis Inc
NYSE:ZTS
|
Revenue
$9.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$87.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$47.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$60.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
14%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$63.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$40.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
7%
|
|
Zoetis Inc
Revenue Breakdown
Breakdown by Geography
Zoetis Inc
|
Total Revenue:
8.5B
USD
|
|
Total Geographical Area:
8.5B
USD
|
|
United States:
4.6B
USD
|
|
Other Emerging Markets:
784m
USD
|
|
Other Developed Markets:
512m
USD
|
|
Brazil:
393m
USD
|
|
Australia:
323m
USD
|
|
China:
320m
USD
|
|
United Kingdom:
277m
USD
|
|
Canada:
255m
USD
|
|
Germany:
202m
USD
|
|
Mexico:
162m
USD
|
|
Japan:
158m
USD
|
|
France:
142m
USD
|
|
Chile:
140m
USD
|
|
Spain:
122m
USD
|
|
Italy:
121m
USD
|
Breakdown by Segments
Zoetis Inc
|
Total Revenue:
8.5B
USD
|
|
Total Products And Services:
8.5B
USD
|
|
Companion Animal:
5.6B
USD
|
|
Horses:
5.3B
USD
|
|
Livestock:
2.9B
USD
|
|
Parasiticides:
1.9B
USD
|
|
Vaccines:
1.8B
USD
|
|
Cattle:
1.5B
USD
|
|
Dermatology:
1.4B
USD
|
|
Other Pharmaceuticals:
1.3B
USD
|
|
Anti-Infectives:
1.1B
USD
|
|
Swine:
543m
USD
|
|
Poultry:
524m
USD
|
|
Animal Health Diagnostics:
376m
USD
|
|
Medicated Feed Additives:
354m
USD
|
|
Dogs And Cats:
285m
USD
|
|
Other Non-Pharmaceuticals:
254m
USD
|
|
Fish:
220m
USD
|
|
Other:
100m
USD
|
|
Contract Manufacturing And Human Health Diagn...:
78m
USD
|
Zoetis Inc
Glance View
Zoetis Inc. is a leading global animal health company dedicated to advancing animal care through innovative solutions that enhance the well-being and productivity of livestock and companion animals. Established in 1952 as a former division of the pharmaceutical giant Pfizer, Zoetis transitioned into its standalone identity in 2013 and has since carved out a significant niche in the growing market for animal health products. With a diverse portfolio that includes vaccines, parasiticides, and diagnostic tools, the company serves farmers, veterinarians, and pet owners, contributing to the health of food-producing animals and pets alike. The robust demand for high-quality animal health products—driven by increasing global food consumption and a growing pet population—positions Zoetis for sustainable growth and offers investors a compelling opportunity. Financially, Zoetis has demonstrated consistent revenue growth, leveraging its strong market presence and commitment to research and development. The company's strategic investments in new technologies and targeted acquisitions have strengthened its position in key market segments. With a focus on driving innovation and addressing changing consumer needs, Zoetis is poised to benefit from emerging trends such as increased attention to food safety and animal welfare. For investors, this translates to a resilient business model with solid long-term prospects, backed by a proven leadership team and a commitment to maintaining a competitive edge through continuous advancement in animal health solutions.
See Also
What is Zoetis Inc's Revenue?
Revenue
9.2B
USD
Based on the financial report for Sep 30, 2024, Zoetis Inc's Revenue amounts to 9.2B USD.
What is Zoetis Inc's Revenue growth rate?
Revenue CAGR 10Y
7%
Over the last year, the Revenue growth was 9%. The average annual Revenue growth rates for Zoetis Inc have been 6% over the past three years , 8% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet
